<?xml version="1.0" encoding="UTF-8"?>
<project>
  <language>en</language>
  <availableLanguages readOnly="true">en</availableLanguages>
  <rcn>253138</rcn>
  <id>101112948</id>
  <acronym>PeptiCHIP</acronym>
  <teaser>Clinical translation of cancer immunotherapies remains very challenging since 60-80% of patients fail to respond.The challenge stands in identifying specific tumour-fingerprints – the neoantigens - that are peptides expressed uniquely by cancer cells and that are capable of...</teaser>
  <objective><![CDATA[Clinical translation of cancer immunotherapies remains very challenging since 60-80% of patients fail to respond.
The challenge stands in identifying specific tumour-fingerprints – the neoantigens - that are peptides expressed uniquely by cancer cells and that are capable of triggering an efficient immune response against cancer. Currently there is no standard method to identify antigens and the few methods available have significant limitations by being quite long, complicated and resource demanding. In response to this clear technological and market gap, Valo Therapeutics (ValoTx, an immunotherapy development company) is introducing PeptiCHIP, i.e. an innovative microfluidic immunopurification device and a peptide prioritisation algorithm to identify the most relevant (neo)antigens to stimulate the immune system and thus increase the chance of success of the immunotherapy. PeptiCHIP can be adapted and used to identify antigens related to any disease. The Proof of Concept (PoC) was successfully demonstrated at University of Helsinki. The IP was protected and ValoTx has full rights to further develop, exploit, and commercialize PeptiCHIP. This EIC Transition project will allow further technology development, testing, validating, and demonstrating it pre-clinically, generating evidence to convince investors and stakeholders, as well as to prepare an extensive and solid transition-to-market plan (T2MP). By being accurate, fast, low-cost, easy to use and working with very small amounts of samples, PeptiCHIP will have great impact in: 1) Research: for discovery & new therapies development since identification of antigens allows the understanding of diseases & immune response mechanisms; 2) Industry: for therapy development & translation into clinical use since the antigens identification & prioritization is a critical step to produce therapies tailored for each patient to ensure responsiveness; 3) Clinic: for patient assessment & immunotherapy tailoring.]]></objective>
  <title>Pre-clinical validation and demonstration of PeptiCHIP: an immunopurification microfluidic device and software for (neo)antigen identification and prioritization</title>
  <keywords>Neoantigens, Oncology, Immunotherapy, Cancer treatment, immune response, immunopeptidomics, proteomics</keywords>
  <totalCost>2226280</totalCost>
  <ecMaxContribution>2226280</ecMaxContribution>
  <startDate>2023-04-01</startDate>
  <endDate>2025-09-30</endDate>
  <ecSignatureDate>2023-03-13</ecSignatureDate>
  <duration>30</duration>
  <status>SIGNED</status>
  <identifiers>
    <grantDoi>10.3030/101112948</grantDoi>
  </identifiers>
  <validation>
    <euroSciVoc>false</euroSciVoc>
  </validation>
  <sourceUpdateDate>2025-10-20 17:38:03</sourceUpdateDate>
  <contentCreationDate readOnly="true">2023-07-11 15:49:42</contentCreationDate>
  <contentUpdateDate>2025-11-19 10:22:21</contentUpdateDate>
  <lastUpdateDate readOnly="true">2025-11-19 10:22:26</lastUpdateDate>
  <relations>
    <associations>
      <call source="corda" type="relatedMasterCall">
        <rcn>55631</rcn>
        <title>HORIZON-EIC-2022-TRANSITION-01</title>
        <identifier>HORIZON-EIC-2022-TRANSITION-01</identifier>
      </call>
      <call source="corda" type="relatedSubCall">
        <rcn>55631</rcn>
        <title>HORIZON-EIC-2022-TRANSITION-01</title>
        <identifier>HORIZON-EIC-2022-TRANSITION-01</identifier>
      </call>
      <organization source="corda" order="1" ecContribution="2226280" sme="true" netEcContribution="2226280" terminated="false" totalCost="2226280" type="coordinator">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>1980969</rcn>
        <id>885471970</id>
        <vatNumber>FI27686954</vatNumber>
        <legalName>VALO THERAPEUTICS OY</legalName>
        <shortName>Valo Therapeutics Oy</shortName>
        <address>
          <street>VIIKINKAARI 6</street>
          <city>Helsinki</city>
          <postalCode>00790</postalCode>
          <country>FI</country>
          <geolocation>60.2265517,25.01371530361569</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/PRC</code>
              <title>Private for-profit entities (excluding Higher or Secondary Education Establishments)</title>
              <displayCode readOnly="true">/Private for-profit entities (excluding Higher or Secondary Education Establishments)</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <name>Helsinki-Uusimaa</name>
              <rcn>1465369</rcn>
              <nutsCode>FI1B1</nutsCode>
              <parents>
                <region>
                  <name>Helsinki-Uusimaa</name>
                  <rcn>1464932</rcn>
                  <nutsCode>FI1B</nutsCode>
                  <parents>
                    <region>
                      <name>Manner-Suomi</name>
                      <rcn>256383528</rcn>
                      <nutsCode>FI1</nutsCode>
                      <parents>
                        <region>
                          <name>Finland</name>
                          <rcn>256543272</rcn>
                          <nutsCode>FI</nutsCode>
                          <euCode>FI</euCode>
                          <isoCode>FI</isoCode>
                        </region>
                      </parents>
                    </region>
                  </parents>
                </region>
              </parents>
            </region>
            <region type="relatedRegion">
              <name>Finland</name>
              <rcn>256543272</rcn>
              <nutsCode>FI</nutsCode>
              <euCode>FI</euCode>
              <isoCode>FI</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <programme source="corda" uniqueProgrammePart="true" type="relatedLegalBasis">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>705792</rcn>
        <id>HORIZON.3.1</id>
        <code>HORIZON.3.1</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.3.1</pga>
        <title>The European Innovation Council (EIC)</title>
        <parent>
          <programme>
            <rcn>705791</rcn>
            <code>HORIZON.3</code>
            <parent>
              <programme>
                <rcn>705725</rcn>
                <code>HORIZON</code>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode readOnly="true">/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme source="corda" type="relatedTopic">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>706907</rcn>
        <id>HORIZON_HORIZON-EIC-2022-TRANSITIONOPEN-01</id>
        <code>HORIZON-EIC-2022-TRANSITIONOPEN-01</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <title>EIC Transition Open 2022</title>
        <parent>
          <programme>
            <rcn>20300</rcn>
            <code>HORIZON-Topics</code>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/topic</code>
              <title>Topic</title>
              <description>Programme: Part of the Commission work programme implementing legal basis</description>
              <displayCode readOnly="true">/Topic</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <result source="corda" type="relatedResult">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>1176000</rcn>
        <id>101112948_PSHORIZON</id>
        <title>Periodic Reporting for period 1 - PeptiCHIP (Pre-clinical validation and demonstration of PeptiCHIP: an immunopurification microfluidic device and software for (neo)antigen identification and prioritization)</title>
        <teaser>Clinical translation of cancer immunotherapies remains very challenging since 60-80% of patients fail to respond. The core of immunotherapy stands in identifying tumour-specific fingerprints – the neoantigens – that are peptides expressed uniquely by cancer cells, capable...</teaser>
        <description>periodic</description>
        <sourceUpdateDate>2024-10-10 22:30:39</sourceUpdateDate>
        <contentUpdateDate>2024-10-21 15:38:18</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/pubsum</code>
              <title>Report Summary</title>
              <description>Result: Publishable summary (FP7 SESAM) and Summary for publication (H2020 SyGMa)</description>
              <displayCode readOnly="true">/Report Summary</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
          <associations>
            <webItem source="corda" type="relatedResultAttachment">
              <language>en</language>
              <availableLanguages readOnly="true">en,any</availableLanguages>
              <uri>/docs/results/horizon/101112/101112948_PS/picture-1.png</uri>
              <alternativeText>PeptiCHIP workflow simplified</alternativeText>
              <mimetype readOnly="true">image/png</mimetype>
              <size readOnly="true">134144</size>
            </webItem>
          </associations>
        </relations>
      </result>
    </associations>
    <categories>
      <category classification="collection" type="belongsTo">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/project</code>
        <title>Project</title>
        <description>Project factsheets</description>
        <displayCode readOnly="true">/Project</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/23/49/315/997</code>
        <title>biomolecules</title>
        <displayCode readOnly="true">/natural sciences/biological sciences/biochemistry/biomolecules</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/digitalAgenda</code>
        <title>Digital agenda</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development of digital technologies and the digitisation of the economy and society (known as ‘Digital transition’).</description>
        <displayCode readOnly="true">/Digital agenda</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/cleanAir</code>
        <title>Clean air</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to the clean air policy (National Emission Ceiling Directive) aiming to improve ambient air quality and tackle air pollution, to protect the environment and human health.</description>
        <displayCode readOnly="true">/Clean air</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/ai</code>
        <title>Artificial intelligence</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development and deployment of AI-based technologies and solutions. Projects that develop AI-tools as part of their research method are included</description>
        <displayCode readOnly="true">/Artificial intelligence</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/climate</code>
        <title>Climate action</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to both mitigating climate change (e.g., contributions to the reduction of greenhouse gas emissions) and adapting to climate change by building resilience (e.g., regarding floods, droughts, spatial planning and better governance, adaptation to changing climate in value chains, etc.).</description>
        <displayCode readOnly="true">/Climate action</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/biodiversity</code>
        <title>Biodiversity</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to Europe’s biodiversity’s path to recovery including species protection, ecosystem conservation, and habitat rehabilitation, all essential for resilience in climate adaptation and addressing ecosystem services but also environmental crime and the health-environment connection.</description>
        <displayCode readOnly="true">/Biodiversity</displayCode>
      </category>
      <category classification="projectFundingSchemeCategory" type="relatedProjectFundingSchemeCategory">
        <language>en</language>
        <availableLanguages readOnly="true">en</availableLanguages>
        <code>/HORIZON-EIC</code>
        <title>HORIZON EIC Grants</title>
        <description>HORIZON EIC Grants</description>
        <displayCode readOnly="true">/HORIZON EIC Grants</displayCode>
      </category>
      <category classification="source" type="isProvidedBy">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/corda</code>
        <title>CORDA</title>
        <description>RTD research data warehouse</description>
        <displayCode readOnly="true">/CORDA</displayCode>
      </category>
    </categories>
  </relations>
</project>
